Beijing Bo'Ente Pharmaceutical Co.,Ltd.

nuBioAge's third annual clinical longevity conference returns February 19–20, bringing together leading physicians, educators, regulatory experts, and industry partners focused on what practitioners need to deliver better care and build stronger practices. FORT LAUDERDALE, Fla., Sept. 30, 2026 /PRNewswire/ -- As longevity medicine grows, so does the number of therapies, technologies, diagnostics, and ideas competing for a practitioner's attention. The harder part is knowing what belongs in clinical practice. That is the focus of CALM: the Clinical Application of Longevity Medicine, returning February 19–20, 2027, at the Omni in Fort Lauderdale, Florida. Continue Reading Leonard Pastrana, founder and CEO of nuBioAge, addresses attendees at the CALM event The CALM stage sets the scene for nuBioAge’s event centered on the future of health, longevity and connection. Now in its third year, the nuBioAge-hosted event is built specifically for the physicians, nurse practitioners, pharmacists, medical leaders, and clinical teams responsible for delivering longevity medicine. Its programming centers on the decisions they make every day: how to evaluate emerging therapies, interpret increasingly complex patient data, use new technology responsibly, build the systems required to deliver care consistently, and determine what is genuinely useful for the patients in front of them. Every year, CALM attendees leave with clinical education, trusted partnerships, and meaningful connections designed to help them deliver better care, build stronger practices, and move longevity medicine forward. Among this year's featured speakers are Amy Killen, MD, Co-Founder and Chief Medical Officer of Humanaut Health and author of the forthcoming The Female Longevity Advantage; Elizabeth Yurth, MD, Co-Founder and Chief Medical Officer of Boulder Longevity Institute and a leading clinician in regenerative, peptide, and cellular medicine; and Tracy Gapin, MD, author of Doctor 2.0 and founder of Peak Launch Institute, where he trains physicians how to scale cash-based precision performance practices. They will be joined by Philip Deibel, MD, FACOG, DipABLM, Founder and CEO of D5 Health; Lexi Yoo, FNP-BC/CPNP, IFMCP, CEO of Yoo Direct Health; along with physicians, practice leaders, regulatory experts, and professionals who advise the FDA. CALM selects speakers not only for their clinical knowledge, but for how they apply it in practice. From nuBioAge Scientific Team members to invited guest speakers, faculty actively treat patients, bring years of experience applying emerging therapies and technologies, and are selected for their ability to translate complex science into practical clinical education. Over two days, the programming will examine the evolving clinical and regulatory landscape surrounding peptide therapy; the real-world use of agentic AI and practice intelligence; how clinicians can turn increasingly sophisticated diagnostics and patient data into clearer treatment decisions; and the infrastructure, operations, and patient experience behind successful longevity practices. The program will also address areas of aging medicine that have historically received less attention, including women's reproductive aging, hormone health, and sexual health, with Killen and Yoo among the clinicians bringing those conversations into the broader longevity discussion. While CALM remains clinically focused, nuBioAge believes excellent care depends on more than clinical knowledge alone. Practitioners also need effective systems, trusted partners, capable teams, and sustainable practice models to deliver a consistently high standard of care. Physicians and operators building successful longevity practices will share what they have learned about creating that infrastructure in the real world. Just as important as the programming is the access around it. CALM is intentionally designed to keep clinicians, educators, technology leaders, and industry partners in conversation beyond the stage. Attendees can ask questions directly, compare approaches with peers, explore potential collaborations, and build relationships that continue long after the event ends. "We built CALM for the people responsible for actually delivering longevity medicine," said Leonard Pastrana, PharmD, Co-Founder of nuBioAge. "As more of the industry moves directly toward consumers, we believe the future of this field should be led by thoughtful, forward-looking medical practitioners. CALM puts the best clinical teachers, the most useful technologies, experts building successful practices, and companies committed to supporting medical practitioners in one room. We want attendees to leave with more than inspiration. We want them to leave with greater confidence, stronger relationships, and practical knowledge they can use to improve patient care." That practitioner-focused approach also shapes the companies nuBioAge brings into the CALM ecosystem. This year, Biote joins CALM as its Foundational Partner, supporting the event at its highest partnership level and playing a central role within the broader longevity ecosystem being assembled around the conference. "Biote is proud to support the advancement of longevity medicine, and we believe hormone optimization is a core component of that future. By bringing together the clinicians, educators, and innovators shaping the future of healthy aging, partnerships like this one are how the field moves forward," said Dr. Komal Bajaj, Chief Medical Officer of Biote. CALM 2027 also welcomes HeadsUp Health, PNOE, and Peak Launch Institute as Integrated Partners, representing complementary areas of technology, diagnostics, clinical assessment, data intelligence, performance, and practice growth. nuBioAge's partnership model centers on complementary capabilities and how these companies can collectively support practitioners—from collecting and interpreting patient data to measuring metabolic function, implementing treatment, and strengthening the systems around clinical care. The exhibit floor extends that ecosystem across precision diagnostics, cardiovascular imaging, genomics, epigenetics, laboratory testing, pharmacy, clinical technology, and patient care, with participating companies including Dutch, Cleerly, IntellxxDNA, InBody, TruDiagnostic, Luqra, Acorn Labs, Vibrant Labs, Ultralight, Zero Gravity, nuHx, and Progress Pharmacy. For medical practitioners deciding what comes next for their patients and practices, CALM is designed to put the right knowledge, resources, and relationships within reach. CALM: the Clinical Application of Longevity Medicine takes place February 19–20, 2027, at the Omni in Fort Lauderdale, Florida. Registration, speaker information, and event details are available at . About CALM CALM, the Clinical Application of Longevity Medicine, is nuBioAge's annual conference for medical practitioners and clinical teams working in longevity medicine. Now in its third year, CALM combines clinical education, applied practice insights, emerging technology, and direct access to physicians, experts, and industry partners advancing the field. About nuBioAge nuBioAge is a longevity science and wellness education network serving medical practitioners and allied health professionals focused on delivering patient-centric, evidence-based longevity medicine. Through its ecosystem of education, research, pharmacy networks, advanced assessments, clinical resources, and industry partnerships, nuBioAge helps practitioners translate emerging longevity science into clinical application. Physician-focused, science-backed, and committed to transparent practices, nuBioAge supports practitioners dedicated to improving healthspan and lifespan outcomes. For more information, visit . Press Contact: Kelli Binnings Director of Ecosystem Partnerships [email protected] Leonard Pastrana PharmD Co-Founder [email protected] SOURCE NUBIOAGE LLC 21% more press release views with Request a Demo

IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving approximately one million patients. “Komal brings an exceptional combination of clinical expertise, operational leadership, quality focus, and innovation mindset to Biote,” said Marc Beer, Chairman of the Board of Biote. “Her experience leading complex healthcare organizations, advancing patient safety and clinical excellence initiatives, and implementing scalable systems that improve patient outcomes will be invaluable as we continue to evolve and strengthen Biote’s provider and patient experience.” Throughout her career, Dr. Bajaj has worked at the intersection of medicine, technology, quality, and human-centered care delivery. She has led large-scale healthcare transformation initiatives involving AI governance, simulation-based workforce training, diagnostic excellence, and patient safety modernization. She also played a leadership role in the development of a prenatal molecular diagnostic assay commercialized internationally and has been instrumental in the launch of several digital health solutions focused on improving data measurement, virtual care, and health professional education. “I am honored to join Biote at such an important time in the Company’s evolution,” said Dr. Bajaj. “Biote has a unique opportunity to expand access to personalized wellness solutions and positively impact patient outcomes at scale. I look forward to partnering with the leadership team, patients, providers, and employees to further strengthen clinical excellence, innovation, quality, and the overall healthcare experience. Dr. Bajaj currently serves as Professor in the Department of Obstetrics, Gynecology and Women’s Health at Albert Einstein College of Medicine and has held numerous national advisory and leadership appointments focused on healthcare quality, safety, diagnostic excellence, and innovation, including the National Academy of Medicine, the Agency for Healthcare Research and Quality (AHRQ), and The Joint Commission. She was recognized as a “Patient Safety Expert To Know” by Becker’s Hospital Review in 2024 and 2025. Bob Peterson added, “Komal’s leadership philosophy strongly aligns with Biote’s culture and our commitment to building a high-performing organization centered on quality, accountability, collaboration, and patient care. We are thrilled to welcome her to the Biote Executive Leadership Team.” About Biote Biote advances the healthspan of our Practitioners’ patients by providing innovative hormone optimization and healthy aging solutions. Through our network of Biote certified providers, we collaborate with leading clinicians to restore vitality and promote vibrant aging. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “outlook,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “hope,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: risks associated with management transitions and the ability of new leadership to execute on the Company’s strategic priorities; our investment in our sales and technology capabilities and its anticipated benefits on our business; anticipated benefits and successful execution of our organizational restructuring; the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers’ reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs, U.S. trade policy or similar government actions; geopolitical tensions; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricanes and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the “Risk Factors” section of Biote’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2026, and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company’s Board of Directors. In addition, Marc Beer, Biote’s Chairman, will assume the role of Executive Chairman. Commenting on the leadership transition, Marc Beer said, “The Board respects Bret’s decision to step down for family and personal reasons and remains focused on maintaining disciplined operational execution and continued strategic progress. We are fortunate to have significant bench strength in Bob Peterson, who was recently promoted to an expanded role of Chief Business Officer in addition to his responsibilities as Chief Financial Officer. Bob has played an integral role in the Company’s financial strategy, operational scaling, and integration of Asteria Health. Bob’s appointment reflects the Board’s confidence in Bob, his capacity to take on greater leadership and his deep knowledge of our operations, strategy and growth priorities. The Board is confident he will provide continuity and clear direction as he leads the Company forward.” Mr. Peterson commented, “I appreciate the confidence of our Board of Directors and am honored to lead our talented team as we pursue our collective goal of becoming the leading provider of evidence-based therapeutic wellness solutions. Over the past twelve months, we have strengthened our commercial organization, expanded our sales team, and enhanced our practitioner support. Through these initiatives, Biote has laid a solid foundation to support sustainable, long-term profitable growth. The Company will continue to advance operational and organizational initiatives already underway to further strengthen scalability, cross-functional execution and long-term growth.” Mr. Beer added, “On behalf of the Board, I want to thank Bret for his strong leadership during an important period of organizational evolution that strengthened the Company’s commercial and operational capabilities. Bret’s leadership has been instrumental during this period, and we are grateful for his continued expertise and insights as a member of the Board.” Mr. Christensen stated, “It has been a privilege to lead Biote during such an important period for the Company and I am proud of the progress our team has made. While stepping away as CEO was not an easy decision, after thoughtful consideration, this is the right time for me to return to Utah and prioritize family and personal matters. I remain confident in the Company’s strategy, leadership team and commercial strength and future direction, and I look forward to continuing to support Biote as a member of the Board of Directors.” Biote reaffirmed its full year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of this year. The Board of Directors has retained an executive search firm to assist with the identification and evaluation of CFO candidates. About Biote Biote advances the healthspan of our Practitioners’ patients by providing innovative hormone optimization and healthy aging solutions. Through our network of Biote certified providers, we collaborate with leading clinicians to restore vitality and promote vibrant aging. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “outlook,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “hope,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: risks associated with management transitions and the ability of new leadership to execute on the Company’s strategic priorities; our investment in our sales and technology capabilities and its anticipated benefits on our business; anticipated benefits and successful execution of our organizational restructuring; the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers’ reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs, U.S. trade policy or similar government actions; geopolitical tensions; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricanes and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the “Risk Factors” section of Biote’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2026, and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations. Contacts Investor Relations: Eric Prouty AdvisIRy Partners eric.prouty@advisiry.com Media: Press@biote.com